Sökning: onr:"swepub:oai:DiVA.org:uu-184952" > Effects on insulin ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03126naa a2200421 4500 | |
001 | oai:DiVA.org:uu-184952 | |
003 | SwePub | |
008 | 121115s2012 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:125423604 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1849522 URI |
024 | 7 | a https://doi.org/10.1530/EJE-12-04842 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1254236042 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Barner, C.4 aut |
245 | 1 0 | a Effects on insulin sensitivity and body composition of combination therapy with GH and IGF1 in GH deficient adults with type 2 diabetes |
264 | 1 | c 2012 |
338 | a print2 rdacarrier | |
520 | a Objective: The aim of this trial was to evaluate the effect on insulin sensitivity and body composition of combination therapy with GH and IGF1 in adults with GH deficiency (GHD) and diabetes. Design, patients and methods: A 6-month randomised placebo-controlled pilot study. Fourteen adults with GHD and type 2 diabetes were included. All received rhGH (0.15 mg/day for 1 month and 0.3 mg/day for 5 months) and were randomised to rhIGF1 (15 μg/kg per day for 1 month and 30 μg/kg per day for 5 months) or placebo. Insulin sensitivity was evaluated with euglycaemic hyperinsulinaemic clamp and body composition by computed tomography of abdominal and thigh fat, as well as bioimpedance. Results: Twelve patients completed the study. They were overweight and obese; at baseline, insulin sensitivity (M-value) was low. IGF1 and IGF1 SDS increased in both groups, with the highest increase in the GH and IGF1 group. Positive changes in M-value by +1.4 mg/kg per min, in subcutaneous abdominal fat by -60.5 ml and in fat-free mass by +4.4% were seen in the GH and IGF1 group. Corresponding values in the GH and placebo-treated group were -1.5 mg/kg per min, +23 ml and -0.04% respectively (P=0.02, P=0.04 and P=0.03 for delta values between groups). No safety issues occurred. Conclusions: Combined GH and IGF1 treatment resulted in positive, but rather small effects, and might be a treatment option in a few selected patients. | |
653 | a Growth-Factor-I | |
653 | a Postmenopausal Women | |
653 | a Replacement Therapy | |
653 | a Hormone Deficiency | |
653 | a Binding-Protein | |
653 | a Glucose | |
653 | a Metabolism | |
653 | a Resistance | |
700 | 1 | a Petersson, M.u Karolinska Institutet4 aut |
700 | 1 | a Engström, Britt Edénu Uppsala universitet,Endokrin diabetes och metabolism4 aut0 (Swepub:uu)brittee |
700 | 1 | a Höybye, C.u Karolinska Institutet4 aut |
710 | 2 | a Karolinska Institutetb Endokrin diabetes och metabolism4 org |
773 | 0 | t European Journal of Endocrinologyg 167:5, s. 697-703q 167:5<697-703x 0804-4643x 1479-683X |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-184952 |
856 | 4 8 | u https://doi.org/10.1530/EJE-12-0484 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:125423604 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy